Marsico Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Marsico Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-57,724	Closed	-$4.6M	–	105
2022 Q2	$4.6M	Hold	57,724	–	–	0.22%	56
2022 Q1	$6.07M	Hold	57,724	–	–	0.21%	58
2021 Q4	$6.22M	Buy	57,724 +17,584	+44%	+$1.92M	0.18%	63
2021 Q3	$4.4M	Hold	40,140	–	–	0.13%	78
2021 Q2	$3.76M	Hold	40,140	–	–	0.09%	78
2021 Q1	$3.69M	Buy	+40,140	New	+$3.39M	0.1%	79

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Marsico Capital Management's HZNP Position: Q3 2022 in Review

Marsico Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 57,724 shares — an estimated $4.6M sold.

Marsico Capital Management first reported a position in HZNP in Q1 2021 and held it in 6 quarters. The position peaked at $6.22M in Q4 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Marsico Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Marsico Capital Management sold 57,724 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $4.6M.
Marsico Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 6 quarters.
Marsico Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.22M in Q4 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Marsico Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.